2017

150.00 rub.
Buy article
2017/№1

Compliance with chronic new oral anticoagulant therapy: Significance of dosing schedule

Pavlova T. V.1, Duplyakov D. V.2
1 – State Budgetary Educational Institution, “Samara State Medical University” of the RF Ministry of Health Care, Chapaevskaya 89, Samara 443099
2 – State Budgetary Educational Institution, “Samara Regional Clinical Cardiology Center”, Aerodromnaya 43, Samara 443070

Keywords: anticoagulants, adherence, rivaroxaban

DOI: 10.18087/rhj.2017.1.2328

Anticoagulant therapy is recommended to most patients with atrial fibrillation (AF). For this purpose, direct oral anticoagulants (DOACs) have been more extensively used in Russia in recent years. In selection of a specific drug of this class, pharmacodynamic and pharmacokinetic features of each drug should be considered. The Factor Xa inhibitor, rivaroxaban is the only DOAC approved in Russia to be used once daily. At the present time, several completed studies have demonstrated that this dosing schedule significantly improved compliance with the therapy and is safe with respect of bleeding incidence.
  1. Colilla S, Crow A, Petkun W, Singer DE, Simon T, Liu X. Estimates of current and future incidence and prevalence of atrial fibrillation in the U. S. adult population. Am J Cardiol. 2013 Oct 15;112 (8):1142–7.
  2. Krijthe BP, Kunst A, Benjamin EJ, Lip GY, Franco OH, Hofman A et al. Projections on the number of individuals with atrial fibrillation in the European Union, from 2000 to 2060. Eur Heart J. 2013 Sep;34 (35):2746–51.
  3. Zoni-Berisso M, Lercari F, Carazza T, Domenicucci S. Epidemiology of atrial fibrillation: European perspective. Clin Epidemiol. 2014 Jun 16;6:213–20.
  4. Hart RG, Pearce LA, Aguilar MI. Meta-analysis: antithrombotic therapy to prevent stroke in patients who have nonvalvular atrial fibrillation. Ann Intern Med. 2007 Jun 19;146 (12):857–67.
  5. Shalansky SJ, Levy AR , Ignaszewski AP. Self-reported Morisky score for identifying nonadherence with cardiovascular medications. Ann Pharmacother. 2004 Sep;38 (9):1363–8.
  6. Cramer JA, Roy A, Burrell A, Fairchild CJ, Fuldeore MJ, Ollendorf DA, Wong PK. Medication compliance and persistence: terminology and definitions. Value Health. 2008 Jan-Feb;11 (1):44–7.
  7. World Health Organization. Adherence to long-term therapies, evidence for action. 2003. Switzerland, WHO. – 2003. – 209p.
  8. Osterberg L, Blaschke T. Adherence to medication. N Engl J Med. 2005 Aug 4;353 (5):487–97.
  9. McHorney CA, Crivera C, Laliberte F, Nelson WW, Germain G, Bookhart B et al. Adherence to non-vitamin-K-antagonist oral anticoagulant medications based on the Pharmacy Quality Alliance measure. Curr Med Res Opin. 2015 Dec;31 (12):2167–73.
  10. Claxton AJ, Cramer J, Pierce C. A systematic review of the associations between dose regimens and medication compliance. Clin Ther. 2001 Aug;23 (8):1296–310.
  11. Saini SD, Schoenfeld P, Kaulback K, Dubinsky MC. Effect of medication dosing frequency on adherence in chronic diseases. Am J Manag Care. 2009 Jun 1;15 (6):e22–33.
  12. Coleman CI, Limone B, Sobieraj DM, Lee S, Roberts MS, Kaur R, Alam T. Dosing frequency and medication adherence in chronic disease. J Manag Care Pharm. 2012 Sep;18 (7):527–39.
  13. Laliberte F, Bookhart BK, Nelson WW, Lefebvre P, Schein JR, Rondeau-Leclaire J, Duh MS. Impact of once-daily versus twice-daily dosing frequency on adherence to chronic medications among patients with venous thromboembolism. Patient. 2013;6 (3):213–24.
  14. Laliberte F, Nelson WW, Lefebvre P, Schein JR , Rondeau-Leclaire J, Duh MS. Impact of daily dosing frequency on adherence to chronic medications among nonvalvular atrial fibrillation patients. Adv Ther. 2012 Aug;29 (8):675–90.
  15. Caldeira D, Vaz-Carneiro A, Costa J. The impact of dosing frequency on medication adherence in chronic cardiovascular disease: systematic review and meta-analysis. Rev Port Cardiol. 2014 Jul-Aug;33 (7-8):431–7.
  16. Weeda ER , Coleman CI, McHorney CA, Crivera C, Schein JR, Sobieraj DM. Impact of once- or twice-daily dosing frequency on adherence to chronic cardiovascular disease medications: a meta-regression analysis. Int J Cardiol. 2016 Aug 1;216:104–9.
  17. Andrade JG, Krahn AD, Skanes AC, Purdham D, Ciaccia A, Connors S. Values and preferences of physicians and patients with nonvalvular atrial fibrillation who receive oral anticoagulation therapy for stroke prevention. Can J Cardiol. 2016 Jun;32 (6):747–53.
  18. McHorney CA, Peterson ED, Laliberte F, Germain G, Nelson WW, Crivera C et al. Comparison of adherence to rivaroxaban versus apixaban among patients with atrial fibrillation. Clin Ther. 2016 Nov;38 (11):2477–88.
  19. Beyer-Westendorf J, Ebertz F, Forster K, Gelbricht V, Michalski F, Kohler C et al. Effectiveness and safety of dabigatran therapy in daily-care patients with atrial fibrillation. Results from the Dresden NOAC Registry. Thromb Haemost. 2015 Jun;113 (6):1247–57.
  20. Beyer-Westendorf J, Forster K, Ebertz F, Gelbricht V, Schreier T, Gobelt M et al. Drug persistence with rivaroxaban therapy in atrial fibrillation patients-results from the Dresden non-interventional oral anticoagulation registry. Europace. 2015 Apr;17 (4):530–8.
  21. Frost C, Song Y, Barrett YC, Wang J, Pursley J, Boyd RA, LaCreta F. A randomized direct comparison of the pharmacokinetics and pharmacodynamics of apixaban and rivaroxaban. Clin Pharmacol. 2014 Nov 13;6:179–87.
  22. Alberts MJ, Peacock WF, Fields LE, Bunz TJ, Nguyen E, Milentijevic D et al. Association between once- and twice-daily direct oral anticoagulant adherence in nonvalvular atrial fibrillation patients and rates of ischemic stroke. Int J Cardiol. 2016 Jul 15;215:11–3.
  23. Mueck W, Eriksson BI, Bauer KA, Borris L, Dahl OE, Fisher WD et al. Population pharmacokinetics and pharmacodynamics of rivaroxaban – an oral, direct factor Xa inhibitor – in patients undergoing major orthopaedic surgery. Clin Pharmacokinet. 2008;47 (3):203–16.
  24. Weitz JI, Connolly SJ, Patel I, Salazar D, Rohatagi S, Mendell J et al. Randomised, parallel-group, multicentre, multinational phase 2 study comparing edoxaban, an oral factor Xa inhibitor, with warfarin for stroke prevention in patients with atrial fibrillation. Thromb Haemost. 2010 Sep;104 (3):633–41.
  25. Agnelli G, Gallus A, Goldhaber SZ, Haas S, Huisman MV, Hull RD et al. Treatment of proximal deep-vein thrombosis with the oral direct factor Xa inhibitor rivaroxaban (BAY 59–7939): the ODIXa-DVT (Oral Direct Factor Xa inhibitor BAY 59–7939 in patients with acute symptomatic deep-vein thrombosis) study. Circulation. 2007 Jul 10;116 (2):180–7.
  26. Salazar DE, Mendell J, Kastrissios H, Green M, Carrothers TJ, Song S et al. Modelling and simulation of edoxaban exposure and response relationships in patients with atrial fibrillation. Thromb Haemost. 2012 May;107 (5):925–36.
  27. Renda G, De Caterina R . The new oral anticoagulants in atrial fibrillation: once daily or twice daily? Vascul Pharmacol. 2013 Sep-Oct;59 (3-4):53–62.
  28. Buller HR , Lensing AW, Prins MH, Agnelli G, Cohen A, Gallus AS et al. A dose-ranging study evaluating once-daily oral administration of the factor Xa inhibitor rivaroxaban in the treatment of patients with acute symptomatic deep vein thrombosis: the Einstein-DVT dose-ranging study. Blood. 2008 Sep 15;112 (6):2242–7.
  29. Mueck W, Lensing AW, Agnelli G, Decousus H, Prandoni P, Misselwitz F. Rivaroxaban: population pharmacokinetic analyses in patients treated for acute deep-vein thrombosis and exposure simulations in patients with atrial fibrillation treated for stroke prevention. Clin Pharmacokinet. 2011 Oct;50 (10):675–86.
  30. Patel MR , Mahaffey KW, Garg J, Pan G, Singer DE, Hacke W et al. Rivaroxaban vs. warfarin in nonvalvular atrial fibrillation. N Engl J Med. 2011 Sep 8;365 (10):883–91.
  31. Camm AJ, Amarenco P, Haas S, Hess S, Kirchhof P, Kuhls S et al. XANTUS: a real-world, prospective, observational study of patients treated with rivaroxaban for stroke prevention in atrial fibrillation. Eur Heart J. 2016 Apr 7;37 (14):1145–53.
  32. Hecker J, Marten S, Keller L, Helmert S, Michalski F, Werth S et al. Effectiveness and safety of rivaroxaban therapy in daily-care patients with atrial fibrillation. Results from the Dresden NOAC Registry. Thromb Haemost. 2016 May 2;115 (5):939–49.
Pavlova T.V., Duplyakov D.V. Compliance with chronic new oral anticoagulant therapy: Significance of dosing schedule. Russian Heart Journal. 2017;16 (1):3–9

To access this material please log in or register

Register Authorize
Ru En